Business Wire

Salute Mission Critical Appoints Erich Sanchack as CEO

Share

Salute Mission Critical, the largest global full lifecycle data center services provider, announces that Erich Sanchack has been appointed Chief Executive Officer. Sanchack succeeds Jason Okroy, the Co-founder of Salute, who will transition to Chief Customer and Strategy Officer.

Sanchack has 30 years of technology and data center experience and joins Salute from Digital Realty Trust. He served there as the Chief Operating Officer responsible for global data center operations, design and construction, colocation and interconnection service implementations, customer operations, supply chain operations, cyber-security, and government and legislative affairs. Prior to Digital Realty Trust, Sanchack held various senior leadership roles at CenturyLink and Lockheed Martin.

“Erich is the right servant leader to elevate our company into the future,” said Lee Kirby, Salute Mission Critical Chairman and Co-founder. “Jason’s leadership over the last decade has been inspirational, and we took our time searching for the right person to guide Salute as we move forward. Furthermore, Erich's experience, skills and knowledge are recognized globally for scaling organizations. As a former United States Marine Corps officer, he is also an outstanding example of the value the military community brings to our industry. Our commercial success allows us to particularly serve the military community, and underserved communities, in even more impactful ways.”

“I am extremely excited to join the Salute Mission Critical team,” said Sanchack. “Salute’s continued success is largely due to its global customer-centric solutions and the full spectrum of high-quality services. The impressive decade of year-over-year growth is a testament to the strength of the Salute team and their ability to deliver. I am honored to be part of Salute’s future. Salute Mission Critical is well positioned to continue to lead the provisioning of their infrastructure services. Additionally, I am thrilled Jason will transition to the Chief Customer and Strategy Officer role, dedicated to supporting customer relationships and ensuring best-in-class customer experiences,” continued Erich Sanchack. "I look forward to the entire team working together to drive even greater value to all stakeholders. Client intimacy is a key lesson learned from the industry that we believe will be integral to our continued differentiator.”

Sanchack earned a B.S. in electrical engineering from The Pennsylvania State University. Additionally, he has been recognized through various programs and awards for his leadership in sustainability, community engagement and veteran stewardship.

About Salute Mission Critical

Salute Mission Critical is the largest global full lifecycle data center services provider that delivers critical facility management services to hyperscale, colocation and edge leaders. Clients worldwide rely on Salute to sustainably operate data centers with military precision.

Follow us on Twitter, Facebook and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Talia Mejia
marketing@saluteinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom